Insider Purchases: Inside the Buy
Tag: Growth Stocks
TTM Technologies (TTMI): CEO Buys the Dip as Revenue Surges 60%—Why Is the Stock Down 63%? 🛰️
TTM Technologies is delivering record earnings, explosive AI infrastructure growth and a $2 billion defense backlog. Its CEO and directors have purchased nearly $3 million in shares—yet TTMI has plunged 63% from its June peak. Is this a rare GARP opportunity or a warning sign? FUNanc1al investigates.
⚛️ Quantinuum (QNT): The $1.6B Quantum Leap, Insiders Loading at $60, and the Multiverse of Single-Digit Sales [Updated Oct. 2026]
Quantinuum's blockbuster IPO and $24 million insider-buying wave highlight the enormous promise—and equally enormous risks—of quantum computing. Revolutionary science, massive losses, and moonshot ambitions make QNT one of the market's most fascinating speculative bets.
GitLab Stock (GTLB): CEO Buys, a Founder Sells—and AI Credits Enter the Code
GitLab delivered 21% revenue growth, improving non-GAAP margins and accelerating AI adoption—but the investment signals remain deliciously contradictory. The CEO is buying, a founder sold approximately $101 million under a prearranged trading plan, quarterly cash flow weakened and dilution remains a concern. Our FunStock Method verdict: promising GARP candidate, but not yet a high-conviction bargain.
🚀 Karman Space & Defense (KRMN): $1.03M Insider Buying, $1.3B Backlog & 58% Revenue Growth
Three Karman Space & Defense directors just bought roughly $1.03 million of KRMN near $37 after a brutal 70% drawdown. Meanwhile, Q2 revenue surged 58%, backlog hit $1.3 billion and guidance rose. The business is firing—but at roughly 44x forward earnings, is the stock finally cheap enough?
🤖 Upstart (UPST): $7.65M Founder Buying Meets a 30.6% Short-Squeeze Fuse 💳⚡
Upstart CEO Paul Gu and Executive Chairman Dave Girouard have bought roughly $7.65 million of UPST stock. Now revenue is growing 42%, GAAP profitability has returned—and 30.6% of the float is short. We dissect one of fintech’s most fascinating battleground stocks.
🚗 Uber (UBER): CEO’s $10M Buy, $10B Free Cash Flow, $14.8B Delivery Hero Deal & the Robotaxi Moat 🍔🤖
Uber CEO Dara Khosrowshahi just bought roughly $10 million of UBER stock near $71. Meanwhile, trailing free cash flow has topped $10 billion, the platform serves 208 million monthly consumers, and robotaxis may prove less existential threat than unexpected opportunity. We unpack the bull case, valuation, risks and an 8.67/10 FunStock Index™ score.
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
💳 Klarna (KLAR): A $10M CEO Buy, 42% TMD Growth & a 75% Post-IPO Crash
Klarna has fallen roughly 75% from its post-IPO high, yet revenue rose 27%, transaction margin dollars surged 42%, and co-founder/CEO Sebastian Siemiatkowski just bought $9.95 million of KLAR. Is Wall Street pricing a broken fintech—or overlooking a rapidly evolving payments platform?
🫀 Boston Scientific (BSX): The CEO Just Bought $9 Million. Is Wall Street Missing Something?
Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.